German biotechnology company Navigo Proteins has established a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, to accelerate development of targeted radiotheranostics. The partnership aims to combine Navigo’s expertise in precision carrier molecules with SCK CEN’s capabilities in radioisotope production and preclinical testing.
Wiley has announced the release of its 2025 edition of the Mass Spectra of Designer Drugs database, a critical resource expanding forensic laboratories’ capabilities in the identification of illicit substances. The updated database represents a substantial advancement in analytical tools available to forensic scientists combating the proliferation of novel psychoactive substances.
New research reveals over 3 million children died globally from AMR-related infections in 2022, with particular concerns about increasing use of critical antibiotic classes.
New research identifies interleukin-6 as a superior diagnostic biomarker for sepsis in high-risk populations including neonates, children, and pregnant women.
Safety concerns prompt Pfizer to terminate development of once-daily oral GLP-1 receptor agonist for weight management, despite promising pharmacokinetic data from recent dose-optimisation studies.
Basel’s equity-free pharma-focused accelerator programme returns to bridge the gap between healthtech innovations and pharmaceutical R&D needs.
Bruker Corporation has announced significant expansions to its infectious disease testing solutions at the ESCMID Global conference in Vienna, including a broader assay menu for its BeGenius® molecular diagnostics system and improvements to its microbial identification platforms.
Beckman Coulter Life Sciences has launched a ground-breaking Next-Generation Basophil Activation Test (BAT) that could transform food allergy research by eliminating the need for potentially dangerous allergen exposure.
Bio-Rad Laboratories has achieved a significant regulatory milestone with EU Quality Management Systems certification under the In Vitro Diagnostic Regulation (IVDR), enabling CE marking for 40 infectious disease molecular quality control products from their Exact Diagnostics brand.
Revvity, Inc. has significantly expanded its collaboration with Genomics England to provide comprehensive genomic screening services for newborns in England. The new agreement builds upon an existing partnership by adding DNA sequencing services to Revvity’s current DNA extraction capabilities.
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.